Pathophysiology, prognosis and treatment of tardive dyskinesia.

"The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: H.T. reports research grants from Daiichi Sankyo and Novartis Pharma; speaker’s fees from EA Pharma, Kyowa, Janssen, Lundbeck, Meiji Seika Pharma, Mochida, Otsuka, Sumitomo Pharma, Takeda and Yoshitomiyakuhin; and advisory board fees from Janssen, Mitsubishi Tanabe Pharma and Sumitomo Pharma. Y.M. reports advisory board fees from Mitsubishi Tanabe Pharma. YT reports speaker’s fees from Janssen, Lundbeck, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, Sumitomo Pharma and Takeda; and advisory board fees from Mitsubishi Tanabe Pharma."

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by Mitsubishi Tanabe Pharma Corporation, who also reviewed the content for medical and scientific accuracy as well as intellectual property considerations."